1. Home
  2. PDSB vs SCLX Comparison

PDSB vs SCLX Comparison

Compare PDSB & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDSB
  • SCLX
  • Stock Information
  • Founded
  • PDSB 2005
  • SCLX 2011
  • Country
  • PDSB United States
  • SCLX United States
  • Employees
  • PDSB N/A
  • SCLX N/A
  • Industry
  • PDSB Biotechnology: Pharmaceutical Preparations
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDSB Health Care
  • SCLX Health Care
  • Exchange
  • PDSB Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • PDSB 43.1M
  • SCLX 51.3M
  • IPO Year
  • PDSB N/A
  • SCLX N/A
  • Fundamental
  • Price
  • PDSB $1.25
  • SCLX $4.67
  • Analyst Decision
  • PDSB Strong Buy
  • SCLX Strong Buy
  • Analyst Count
  • PDSB 3
  • SCLX 4
  • Target Price
  • PDSB $10.00
  • SCLX $396.67
  • AVG Volume (30 Days)
  • PDSB 275.1K
  • SCLX 116.9K
  • Earning Date
  • PDSB 05-14-2025
  • SCLX 05-12-2025
  • Dividend Yield
  • PDSB N/A
  • SCLX N/A
  • EPS Growth
  • PDSB N/A
  • SCLX N/A
  • EPS
  • PDSB N/A
  • SCLX N/A
  • Revenue
  • PDSB N/A
  • SCLX $56,590,000.00
  • Revenue This Year
  • PDSB N/A
  • SCLX $115.30
  • Revenue Next Year
  • PDSB N/A
  • SCLX $73.33
  • P/E Ratio
  • PDSB N/A
  • SCLX N/A
  • Revenue Growth
  • PDSB N/A
  • SCLX 21.07
  • 52 Week Low
  • PDSB $0.85
  • SCLX $5.80
  • 52 Week High
  • PDSB $4.42
  • SCLX $80.50
  • Technical
  • Relative Strength Index (RSI)
  • PDSB 55.58
  • SCLX 30.26
  • Support Level
  • PDSB $1.00
  • SCLX $3.60
  • Resistance Level
  • PDSB $1.17
  • SCLX $7.64
  • Average True Range (ATR)
  • PDSB 0.11
  • SCLX 1.15
  • MACD
  • PDSB 0.04
  • SCLX -0.25
  • Stochastic Oscillator
  • PDSB 81.61
  • SCLX 16.34

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: